TLE-1 immunoreactivity in angiomatoid fibrous histiocytoma: a potential diagnostic pitfall

Angiomatoid Fibrous Histiocytoma: Case Presentation with Review of Literature

“…Angiomatoid Fibrous Histiocytoma is a rare tumor that was first described by Enzinger in 1979 [1]. It was originally believed to be quite an aggressive neoplasm with uncertain histogenesis, mainly affecting children and young adults, and often involving superficial soft tissues of the extremities [2], although rare cases have been reported in other locations, such as intracranial [3][4][5], spinal [6] or chest wall [7]. In terms of prevalence, AFH accounts for 0.3% of all soft tissue cancers [2] and is classified by the World Health Organization (WHO 2020) as a mesenchymal neoplasm of uncertain differentiation and intermediate malignant biological behavior.…”

“…A summary of the immunohistochemical markers that can be used for a correct differential diagnosis is given in Table 1. Recently, Xiang et al reported two of only three cases of AFH, showing positivity for TLE-1, a nuclear marker used for some tumors belonging to the Synovial Sarcoma family [7]. In 2020, Abrahao-Machado et al described 18 cases of AFH, 4 of which expressed MUC-4 (22.2%).…”